Minerva Surgical, Inc. is a medical technology company. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.
Mr. Todd Usen is the President of Minerva Surgical Inc, joining the firm since 2023.
What is the price performance of UTRS stock?
The current price of UTRS is $0.0001, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Minerva Surgical Inc?
Minerva Surgical Inc belongs to Health Care industry and the sector is Health Care
What is Minerva Surgical Inc market cap?
Minerva Surgical Inc's current market cap is $888
Is Minerva Surgical Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Minerva Surgical Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell